Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity

We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.0...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Jung, Dong Sik, Tverdek, Frank P., Kontoyiannis, Dimitrios P.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2014
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249440/
https://ncbi.nlm.nih.gov/pubmed/25199774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04035-14
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars